SPONSORED CLINICAL STUDY AGREEMENTSponsored Clinical Study Agreement • June 23rd, 2005 • Chemgenex Pharmaceuticals LTD • American depositary receipts • Texas
This Clinical Study Agreement (the “Agreement”) is made this 14th day of April, 2003 (“Effective Date”), between The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030 (“Institution”), a component of The University of Texas System (“System”), and ChemGenex Therapeutics, Inc., 3475 Edison Way, Suite M, Menlo Park, California 94025 (“Sponsor”). Institution and Sponsor agree as follows:
SPONSORED CLINICAL STUDY AGREEMENTSponsored Clinical Study Agreement • July 15th, 2009 • Texas
THIS AGREEMENT is made this _______ day of _______________ 20___, between The University of Texas ________, whose address is ______________ ("INSTITUTION"), a component institution of The University of Texas System ("SYSTEM"), and Abbott Laboratories whose address is One Abbott Park Road, Abbott Park, Illinois 60064 ("SPONSOR"), to conduct a clinical study and evaluation ("STUDY"). INSTITUTION and SPONSOR agree as follows:
SPONSORED CLINICAL STUDY AGREEMENTSponsored Clinical Study Agreement • July 15th, 2009 • Texas
THIS AGREEMENT is made this _______ day of _______________ 19___, between The University of Texas _______, whose address is _________("INSTITUTION"), a component institution of The University of Texas System ("SYSTEM"), and Abbott Laboratories whose address is One Abbott Park Road, Abbott Park, Illinois 60064 ("SPONSOR"), to conduct a clinical study and evaluation ("STUDY"). INSTITUTION and SPONSOR agree as follows:
